Professor Yang Deokhwan of Hwasun Chonnam National University Hospital Appointed Chairman of the Lymphoma Research Committee of the Korean Society of Hematology

Professor Yang Deok-hwan of the Department of Hematology at Hwasun Jeonnam National University Hospital has been appointed as the chairman of the Lymphoma Research Committee of the Korean Society of Hematology. The term is three years, from January 1, 2024, to December 31, 2026.

According to Hwasun Jeonnam National University Hospital on the 26th, the Lymphoma Research Committee under the Korean Society of Hematology, which includes members of the Korean Society of Hematology, is a research group dedicated to finding solutions for the diagnosis and treatment of malignant lymphoma diseases.

Recently, the committee has been leading clinical research that establishes treatment guidelines and proposes the latest therapies, playing a central role in lymphoma treatment both domestically and internationally.

Professor Yang currently treats malignant lymphoma and osteoproliferative tumors in the field of hematologic cancers at Hwasun Jeonnam National University Hospital. He has been recognized academically for his research in areas such as immunotherapy using T cells and programs predicting treatment response and prognosis in hematologic cancer patients using artificial intelligence.

Notably, in 2021, the research team led by Professor Yang was the first in the world to demonstrate that combining the targeted anticancer drug copanlisib with the cytotoxic anticancer drug gemcitabine enhances treatment efficacy. The research results were published in the prestigious international cancer journal, Annals of Oncology.

He currently serves as a director of both the Korean Society of Hematology and the Korean Society for Hematopoietic Stem Cell Transplantation. In 2022, he received the Mid-Career Researcher Award from the Korean Society of Hematology and continues to actively engage in research and academic activities within the society.

Professor Yang stated, “We plan to continuously conduct extensive basic research and clinical studies that meet international standards to advance lymphoma treatment in Korea,” adding, “We will strive to make the research committee dedicated to improving treatment outcomes for lymphoma patients.”

This content was produced with the assistance of AI translation services.